Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Cancer MedicineJun 8, 2026
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France

Clinical Context

We think this might be relevant to the clinical guidance for TNM 9th Ed (NSCLC).

Cancer MedicineJun 8, 2026
Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines

Clinical Context

We think this has broad domain relevance to TNM 9th Ed (NSCLC).

DiabetologiaJun 5, 2026
Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes

Clinical Context

We think this has broad domain relevance to TNM 9th Ed (NSCLC).

TNM 9th Ed (NSCLC)

TNM 9TH EDNSCLC Lung Cancer Staging

Clinical Staging Assignment

Note: The 9th edition of the TNM staging system for lung cancer was implemented in 2024, providing refined T-descriptors and updated survival data.

Stage Interpretation

Stage IA1

Clinical Framing

Early-stage localized lung cancer. Often eligible for surgical resection or stereotactic radiation (SBRT).

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Staging of all Non-Small Cell Lung Cancer (Adenocarcinoma, Squamous Cell, Large Cell).
Used to determine surgical resectability and the need for neoadjuvant or adjuvant systemic therapy.
Initial clinical staging (cTNM) via PET-CT and EBUS/Mediastinoscopy.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the TNM 9th Ed (SCLC), PD-L1 TPS Interpretation, Lung-RADS v2022 or the NSCLC GPA to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

TNM 9th Ed
PD-L1 TPS Interpretation
Lung-RADS v2022
NSCLC GPA
ASTCT Grading
IPSS-M
SINS Score
MRD Assessment Framework
ELN 2022 Risk
Opioid Equianalgesic
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.